 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > BioMarin Pharmaceutical Inc.
 |
BioMarin Pharmaceutical Inc. |
 |
 |
 |
PROFILE |
 |
If you're feeling something's missing, BioMarin Pharmaceutical can help -- if that something is (alpha)-L-iduronidase. That enzyme is missing in patients with the life-threatening inherited condition mucopolysaccharidosis-I, or MPS-I. Because only 3,400 known patients suffer from the disease, the company's treatment, Aldurazyme, has received orphan drug status from the FDA. This gives the development-stage firm exclusive seven-year rights to market Aldurazyme if it is the first enzyme for MPS-1 that is OK'd by the FDA. The company will market the drug through a joint venture with Genzyme. BioMarin, of which Glyko Biomedical owns about 30%, is also developing enzymes that target burns.
COMPETITION |
 |
BioCryst Pharmaceuticals, Inc. (BCRX)
Biospecifics Technologies Corp. (BSTC)
Enzon, Inc. (ENZN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 12.30
1-Yr. Sales Growth: 75.7%
Employees: 174
Revenue per employee: $70,689.66
KEY PEOPLE |
 |
Fredric D. Price
CEO
Raymond W. Anderson
CFO
CONTACT INFO |
 |
371 Bel Marin Keys Blvd., Ste. 210
Novato, CA 94949
US
Phone: 415-884-6700
Fax: 415-382-7427
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |